Methoxsalen G.L. Pharma (Methoxsalen)

Methoxsalen intercalates into DNA and, when activated by UVA radiation, creates cross‑links that block DNA synthesis and cell division. This photochemical action reduces abnormal cell proliferation in the skin and immune system, leading to clinical improvement in the treated conditions.

The dosage of methoxsalen is individualized by the prescribing clinician based on the specific indication, patient weight, and response to therapy. Dosing regimens are determined during a supervised PUVA treatment plan and should not be altered without medical guidance.

Methoxsalen is classified as Pregnancy Category D, indicating evidence of risk to the fetus; it should only be used if the potential benefit justifies the risk. It is not recommended during breastfeeding because it can be secreted in breast milk and may affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Methoxsalen is a first‑generation psoralen and is widely used in PUVA protocols because of its well‑characterized efficacy and safety profile. Compared with newer synthetic psoralens, methoxsalen has a longer history of clinical use, but may require more stringent photoprotection measures due to its potent photosensitizing effect.

Methoxsalen should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct light. Maintaining these conditions helps preserve its stability and potency for extracorporeal use.

Methoxsalen is administered extracorporeally, typically as a solution that is added to the patient's blood during photopheresis or taken orally prior to controlled UVA exposure in PUVA therapy. The exact route and timing are determined by the treating physician.

Serious risks include severe phototoxic burns, blistering, blood dyscrasias such as leukopenia, hepatic dysfunction, and rare anaphylactic reactions. Patients should be monitored closely for these events, especially during the initial phases of treatment.

Methoxsalen should be avoided in patients with known hypersensitivity to psoralens, those with active skin infections, uncontrolled liver disease, or in individuals who cannot adhere to strict photoprotection measures. It is also contraindicated during pregnancy unless absolutely necessary.